• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

AVOS Life Sciences Releases Diabetes Research Report

Posted on: Wednesday, 5 December 2007, 09:01 CST

MORRISVILLE, N.C., Dec. 5 /PRNewswire/ -- According to the Diabetes Therapeutic Market Outlook (TMO), released today by AVOS Life Sciences, the diabetes segment is projected to grow robustly through 2010 before flattening with peak total prescription drug revenue around $13 billion. DPP-IV inhibitors and GLP-1s are the new growth drivers in this market as additional drug classes to manage diabetes progression prior to use of the long-standing insulin products, with a predicted CAGR of 33% for the DPP-IV inhibitor class during 2007-2013. This report is the latest in a series of in-depth research reports that analyze the pharmaceutical industry. The Diabetes TMO frames and quantifies the impact of evolving treatment approaches on the ethical pharmaceutical sector with consideration of key market-shaping trends. For example, therapeutic substitution effects are modeled to project the impact on the key branded drug facing loss of exclusivity as well as the potential market share impact on other branded competitors.

The report provides detailed forecasts and revenue models with seven-year projections for unit volume/pricing for all major brand diabetes drugs on the market or in late-stage clinical development. Each report also includes input from the AVOS Physician Panel detailing their prescribing patterns and their expectations regarding market dynamics that will influence the success or failure of current and pipeline diabetes drugs.

"AVOS' clients are key executives in leading pharma/biotech companies, PBMs and the financial services industry," said Neil MacAllister, President of AVOS Life Sciences. "They rely on accurate metrics to make sound, objective decisions. The right information can reduce the turn-around time for product development/acquisition by as much as 25%."

According to MacAllister, "Our clients have found that the disease-driven view that AVOS takes with its TMO Reports offers a robust, objective snapshot of a therapeutic market. TMO reports reveal market growth drivers and emerging technologies, in addition to identifying leading pipeline products. This assessment creates a strategic advantage in product development efforts and provides critical vision into specific markets for investment purposes."

"One of AVOS' strengths," stated Richard Evans, Vice President at AVOS, "is our first hand experience gained through extensive consulting engagements delivering strategic, operational and financial insight to healthcare and life science companies. Our perspective allows us to analyze financial market conditions in a holistic way and greatly adds to our forecasting abilities and market assessments. We are able to offer our clients a full understanding of capital market reactions."

TMO Reports are available from AVOS Life Sciences on a subscription basis or individually at competitive prices. Recent TMO Reports include - Diabetes, Antidepressants and Lipid Modulating Agents. Future reports will highlight Anticonvulsants, Antipsychotics, Asthma/COPD, Cardiovascular, Obesity, Rhinitis, Sleep Disorders, and Osteoporosis. Reports can be ordered from http://www.avoslifesciences.com/, by calling Paul Holgate at 919-459-1817 or emailing pholgate@avoslifesciences.com. A free sample report is available by registering at http://avoslifesciences.com/registration.php.

AVOS Life Sciences, LLC provides strategic, operational and financial consulting services to the healthcare industry. AVOS helps clients fully understand the pharmaceutical, biotechnology, medical device and diagnostic market segments, and assists with strategic business development and investment choices. AVOS' analytical marketing research tools are structured to facilitate real-time decision-making in a dynamic environment, saving organizations significant time and money directly impacting the bottom line.

AVOS Life Sciences, LLC

CONTACT: Kathleen Griffin of AVOS Life Sciences, LLC, +1-866-728-8942,Fax: +1-919-459-1839, kgriffin@avoslifesciences.com

Web site: http://www.avoslifesciences.com/http://avoslifesciences.com/registration.php

Source: PRNewswire

More News in this Category